STAT1 and B-cell biomarkers (CD19 and CD79A), CD8+ T-cell biomarkers (CD8A and CD8B), CD4+ T-cell biomarkers (CD4), M1 macrophage biomarkers (NOS2, IRF5, and PTGS2), M2 macrophage biomarkers (CD163, VSIG4, and MS4A4A), neutrophil biomarkers (ITGAM and CCR7), and dendritic cell biomarkers in HCC (HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DPA1, CD1C, NRP1, and ITGAX) are shown in Table 2. This evidence concerns the gene CD163 and hepatocellular carcinoma.